The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Open accessAbstract
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5. METHODS: We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were stratified according to blood eosinophil count (≥150 per cubic millimeter at screening or ≥300 per cubic millimeter during the previous year). In METREO, all patients had a blood eosinophil count of at least 150 per cubic millimeter at screening or at least 300 per cubic millimeter during the previous year. The primary end point was the annual rate of moderate or severe exacerbations. Safety was also assessed. RESULTS: In METREX, the mean annual rate of moderate or severe exacerbations in the modified intention-to-treat population with an eosinophilic phenotype (462 patients) was 1.40 per year in the mepolizumab group versus 1.71 per year in the placebo group (rate ratio, 0.82; 95% confidence interval [CI], 0.68 to 0.98; adjusted P=0.04); no significant between-group differences were found in the overall modified intention-to-treat population (836 patients) (rate ratio, 0.98; 95% CI, 0.85 to 1.12; adjusted P>0.99). In METREO, the mean annual rate of moderate or severe exacerbations was 1.19 per year in the 100-mg mepolizumab group, 1.27 per year in the 300-mg mepolizumab group, and 1.49 per year in the placebo group. The rate ratios for exacerbations in the 100-mg and 300-mg mepolizumab groups versus the placebo group were 0.80 (95% CI, 0.65 to 0.98; adjusted P=0.07) and 0.86 (95% CI, 0.70 to 1.05; adjusted P=0.14), respectively. A greater effect of mepolizumab, as compared with placebo, on the annual rate of moderate or severe exacerbations was found among patients with higher blood eosinophil counts at screening. The safety profile of mepolizumab was similar to that of placebo. CONCLUSIONS: Mepolizumab at a dose of 100 mg was associated with a lower annual rate of moderate or severe exacerbations than placebo among patients with COPD and an eosinophilic phenotype. This finding suggests that eosinophilic airway inflammation contributes to COPD exacerbations. (Funded by GlaxoSmithKline; METREX and METREO ClinicalTrials.gov numbers, NCT02105948 and NCT02105961 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
Development and first validation of the COPD Assessment Test
Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W.-H., & Kline Leidy, N. (2009) · European Respiratory Journal · doi:10.1183/09031936.00102509 · Cited by 3,198
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Self-citationPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Self-citationBafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., McCormick, M., Haldar, K., Kebadze, T., Duvoix, A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201104-0597oc · Cited by 1,094
Self-citationPascoe, S., Locantore, N., Dransfield, M. T., Barnes, N. C., & Pavord, I. D. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00106-x · Cited by 743
Self-citationBafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., Lomas, D. A., Barer, M. R., Johnston, S. L., Pavord, I. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1553oc · Cited by 612
Self-citationChupp, G. L., Bradford, E. S., Albers, F. C., Bratton, D. J., Wang-Jairaj, J., Nelsen, L. M., Trevor, J. L., Magnan, A., & ten Brinke, A. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30125-x · Cited by 599
Self-citationBrightling, C. E., Monteiro, W., Ward, R., Parker, D., Morgan, M. D., Wardlaw, A. J., & Pavord, I. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02872-5 · Cited by 595
Self-citationInterpreting thresholds for a clinically significant change in health status in asthma and COPD
Jones, P. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00063702 · Cited by 585
Ortega, H. G., Yancey, S. W., Mayer, B., Gunsoy, N. B., Keene, O. N., Bleecker, E. R., Brightling, C. E., & Pavord, I. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30031-5 · Cited by 559
Self-citationEosinophilic inflammation in COPD: prevalence and clinical characteristics
Singh, D., Kolsum, U., Brightling, C. E., Locantore, N., Agusti, A., & Tal-Singer, R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00162414 · Cited by 497
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial
Siva, R., Green, R. H., Brightling, C. E., Shelley, M., Hargadon, B., McKenna, S., Monteiro, W., Berry, M., Parker, D., Wardlaw, A. J., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00146306 · Cited by 453
Self-citationCrim, C., Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Willits, L. R., Yates, J. C., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00193908 · Cited by 432
Vestbo, J., Papi, A., Corradi, M., Blazhko, V., Montagna, I., Francisco, C., Cohuet, G., Vezzoli, S., Scuri, M., & Singh, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30188-5 · Cited by 425
Siddiqui, S. H., Guasconi, A., Vestbo, J., Jones, P., Agusti, A., Paggiaro, P., Wedzicha, J. A., & Singh, D. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0235le · Cited by 415
Meguro, M., Barley, E. A., Spencer, S., & Jones, P. W. (2007) · Chest · doi:10.1378/chest.06-0702 · Cited by 350
Dransfield, M. T., Bourbeau, J., Jones, P. W., Hanania, N. A., Mahler, D. A., Vestbo, J., Wachtel, A., Martinez, F. J., Barnhart, F., Sanford, L., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70040-7 · Cited by 345
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
Pavord, I. D., Lettis, S., Locantore, N., Pascoe, S., Jones, P. W., Wedzicha, J. A., & Barnes, N. C. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207021 · Cited by 327
Self-citationBrightling, C. E., Bleecker, E. R., Panettieri, R. A., Bafadhel, M., She, D., Ward, C. K., Xu, X., Birrell, C., & van der Merwe, R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70187-0 · Cited by 315
Hart, T. K., Cook, R. M., Zia-Amirhosseini, P., Minthorn, E., Sellers, T. S., Maleeff, B. E., Eustis, S., Schwartz, L. W., Tsui, P., Appelbaum, E. R., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.116576 · Cited by 238
Pavord, I. D., Lettis, S., Anzueto, A., & Barnes, N. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30148-5 · Cited by 184
Self-citationVarricchi, G., Bagnasco, D., Borriello, F., Heffler, E., & Canonica, G. W. (2016) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000251 · Cited by 177
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis
Bafadhel, M., Davies, L., Calverley, P. M. A., Aaron, S. D., Brightling, C. E., & Pavord, I. D. (2014) · European Respiratory Journal · doi:10.1183/09031936.00062614 · Cited by 167
Self-citationReported Pneumonia in Patients With COPD
Calverley, P. M. A., Stockley, R. A., Seemungal, T. A. R., Hagan, G., Willits, L. R., Riley, J. H., & Wedzicha, J. A. (2011) · Chest · doi:10.1378/chest.09-2992 · Cited by 161
Missing data sensitivity analysis for recurrent event data using controlled imputation
Keene, O. N., Roger, J., Hartley, B. F., & Kenward, M. G. (2014) · Pharmaceutical Statistics · doi:10.1002/pst.1624 · Cited by 51
Jones, P., Shahrour, N., Nejjari, C., Lahlou, A., Doble, A., Rashid, N., & Hasnaoui, A. E. (2012) · Respiratory Medicine · doi:10.1016/s0954-6111(12)70017-3 · Cited by 32
Cited by
Chronic obstructive pulmonary disease
Christenson, S. A., Smith, B. M., Bafadhel, M., & Putcha, N. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00470-6 · Cited by 1,219
Biologic Therapies for Severe Asthma
Brusselle, G. G., & Koppelman, G. H. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032506 · Cited by 715
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
Stolz, D., Mkorombindo, T., Schumann, D. M., Agusti, A., Ash, S. Y., Bafadhel, M., Bai, C., Chalmers, J. D., Criner, G. J., Dharmage, S. C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01273-9 · Cited by 681
Self-citationManagement of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00588-2019 · Cited by 629
Self-citationDupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Bhatt, S. P., Rabe, K. F., Hanania, N. A., Vogelmeier, C. F., Cole, J., Bafadhel, M., Christenson, S. A., Papi, A., Singh, D., Laws, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303951 · Cited by 521
Metadata
- Authors
- Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N., Martinot, J.-B., Sagara, H., Albers, F. C., Bradford, E. S., Harris, S. S., Mayer, B., Rubin, D. B., Yancey, S. W., & Sciurba, F. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-26
- Volume
- 377
- Issue
- 17
- Pages
- 1613-1629
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2756335179
- Cited by
- 625
- References
- 27
- FWCI
- 46.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.